A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain.
Tamar TadmorAndrei BraesterDally NajibAriel AvivYair HerishanuMona YukleaLev ShvidelNaomi Rahimi-LeveneRosa RuchlemerAriela AradClaudia FoglClara HenigMira BarakLee MagalAaron PolliackKelly Townsendnull nullPublished in: European journal of haematology (2019)
The above findings demonstrate the potential for the use of HLC immunoparesis, together with sFLC measurements, as future prognostic biomarkers in CLL.